[Glioblastoma multiforme--new hope due to modern therapeutical approaches].
Glioblastoma multiforme (GBM) is the most frequently encountered malignant cerebral tumor. Despite significant improvements in the treatment of GBM, this disease remains associated with a high morbidity and mortality, with more than half of all affected patients dying within the first year after diagnosis. Typical symptoms include focal neurological symptoms, seizures, personality changes and neurocognitive symptoms. GBM can be identified by means of cerebral imaging modalities and subsequently confirmed histopathologically through biopsy or resection. At present, surgical resection followed by radiotherapy with concomitant chemotherapy with temozolomide and subsequent adjuvant chemotherapy with temozolomide is considered the standard therapy for patients with GBM. Currently, many interdisciplinary studies with glioblastoma patients are accomplished with the aim to further improve the prognosis of the affected patients.
Gautschi
O P
OP
Klinik für Neurochirurgie, Kantonsspital St. Gallen, Rorschacher Strasse 95, St. Gallen. Oliver.Gautschi@kssg.ch
Cadosch
D
D
Collen
T D
TD
Land
M
M
Hoederath
P
P
Hildebrandt
G
G
Fournier
J-Y
JY
Hundsberger
T
T
D000465:Algorithms; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005909:Glioblastoma / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D011379:Prognosis; D000077204:Temozolomide; D013997:Time Factors
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide